Focal Takotsubo Cardiomyopathy With High-Dose Interleukin-2 Therapy for Malignant Melanoma

被引：10

作者：

Damodaran, Senthil ^{[1
]}

Mrozek, Ewa ^{[1
]}

Liebner, David ^{[1
]}

Kendra, Kari ^{[1
]}

机构：

[1] Ohio State Univ, Wexner Med Ctr, Div Med Oncol, Columbus, OH 43210 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2014年 / 12卷 / 12期

关键词：

REVERSIBLE CARDIOMYOPATHY; METASTATIC MELANOMA;

D O I：

10.6004/jnccn.2014.0168

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-dose interleukin-2 (IL-2) is an available treatment option for patients with metastatic melanoma or renal cell carcinoma, and is associated with sustained complete and partial responses in a subset of patients. IL-2, however, is not devoid of toxicities, most of which involve the cardiovascular system and manifest as hypotension, arrhythmias, and cardiomyopathy. This report describes an unusual presentation of takotsubo cardiomyopathy in a postmenopausal woman receiving high-dose IL-2 for metastatic melanoma.

引用

页码：1666 / 1670

页数：5

共 50 条

[21] Management of metastatic melanoma to the breast with high-dose interleukin-2 and surgical resection
Komenaka, IK
Deraffele, G
Hurst-Wicker, KS
Kaufman, HL
BREAST JOURNAL, 2005, 11 (02): : 158 - 159
[22] Administration of High-Dose Interleukin-2 in a 2-Year-Old With Metastatic Melanoma
Bernhardt, M. Brooke
Hicks, M. John
Pappo, Alberto S.
PEDIATRIC BLOOD & CANCER, 2009, 53 (07) : 1346 - 1348
[23] COLONIC PERFORATION - AN UNUSUAL COMPLICATION OF THERAPY WITH HIGH-DOSE INTERLEUKIN-2
SCHWARTZENTRUBER, D
LOTZE, MT
ROSENBERG, SA
CANCER, 1988, 62 (11) : 2350 - 2353
[24] Managing toxicities of high-dose interleukin-2
Schwartz, RN
Stover, L
Dutcher, J
ONCOLOGY-NEW YORK, 2002, 16 (11): : 11 - 20
[25] COMPLEMENT ACTIVATION AND HIGH-DOSE OF INTERLEUKIN-2
THIJS, LG
HACK, CE
VANSCHIJNDEL, RJMS
NUIJENS, JH
WOLBINK, GJ
EERENBERGBELMER, AJM
VANDERVALL, H
WAGSTAFF, J
LANCET, 1989, 2 (8659): : 395 - 395
[26] Syndrome of Inappropriate Antidiuretic Hormone Secretion Caused by High-Dose Bolus Interleukin-2 Therapy for Metastatic Melanoma
Green, Myke R.
Woolery, Joseph E.
Elquza, Emad
AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (05) : E159 - E161
[27] High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
Atkins, MB
Kunkel, L
Sznol, M
Rosenberg, SA
CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 2000, 6 : S11 - S14
[28] High-Dose Interleukin-2: Is It Still Indicated for Melanoma and RCC in an Era of Targeted Therapies?
Amin, Asim
White, Richard L., Jr.
ONCOLOGY-NEW YORK, 2013, 27 (07): : 680 - 691
[29] High-Dose Intensity Pulse Interleukin-2 with Famotidine Has Activity in Metastatic Melanoma
Quan, Walter D. Y., Jr.
Walker, Paul R.
Picton, Maria
Quan, Francine M.
King, Linda A.
Tyre, Charley
Liles, Darla K.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (05) : 641 - 646
[30] INTERLEUKIN-2 AND HIGH-DOSE CISPLATIN IN PATIENTS WITH METASTATIC MELANOMA - A PILOT-STUDY
DEMCHAK, PA
MIER, JW
ROBERT, NJ
OBRIEN, K
GOULD, JA
ATKINS, MB
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) : 1821 - 1830

← 1 2 3 4 5 →